Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 47.05%의 증가율을 기록했습니다.
공정한 가치
회사의 최신 PE은 -10.33로, 최근 3년 기준 중간 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 50.03M주이며, 전 분기 대비 24.26% 감소했습니다.